REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS (Tables)

12 Months Ended

Dec. 31, 2019

REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreement was as follows:

	Year Ended December 31,
(In thousands)	2019		2018		2017
Royalties from a related party — RELVAR/BREO	$	189,424	$	220,162	$	198,726
Royalties from a related party — ANORO		42,625		41,286		29,036
Royalties from a related party — TRELEGY		42,790		13,379		179
Total royalties from a related party		274,839		274,827		227,941
Less: amortization of capitalized fees paid to a related party		(13,823)		(13,823)		(13,823)
Royalty revenue		261,016		261,004		214,118
Strategic alliance  — MABA program license		—		—		3,099
Total net revenue from GSK	$	261,016	$	261,004	$	217,217